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Human metapneumovirus (HMPV) is a common virus that can cause respiratory problems ranging from mild upper respiratory
tract disease to respiratory failure requiring mechanical support. Here, we report a case of a 32-month-old male with a previous
history of asthma, who developed respiratory failure two weeks after onset of cough and rhinorrhea and required extracorporeal
membrane oxygenation (ECMO) for 9 days after failing high-frequency oscillatory ventilation (HFOV). To our knowledge, this
is the oldest reported pediatric patient with respiratory failure secondary to human metapneumovirus that did not respond to
mechanical ventilation. This case highlights three critical points: the potentially fatal causative role of HMPV in respiratory failure
in an older pediatric age group of immunocompetent hosts, the importance of early recognition of impending respiratory failure,
and the timely utilization of ECMO.
1.Background
Human metapneumovirus, an RNA virus in the paramyx-
ovirus family, was ﬁrst isolated from 28 patients in The
Netherlands in 2001. The spectrum of disease ranges from
mild upper respiratory tract disease to severe bronchiolitis
and pneumonia requiring mechanical ventilation [1].
There have been four reported cases of pediatric patients
withHMPV-inducedrespiratoryfailurewhodidnotrespond
to mechanical ventilation: a 17-month-old with acute lym-
phocytic leukemia receiving chemotherapy who died of
respiratory failure [2]; a three-month-old infant with history
of premature birth at 27 weeks who survived after ECMO
[3];anine-month-oldinfantonimmunosuppressivetherapy
after a liver transplant for biliary atresia who also survived
after ECMO [4], and a two-year-old previously healthy
immunocompetent girl who died of pulmonary hemorrhage
while on conventional ventilation [5]. Here, we present the
case of a thirty-two-month-old immunocompetent boy with
HMPV-induced respiratory failure and a history of asthma
who was supported with ECMO and survived.
2. Case Presentation
The patient is a 32-month-old male with a history of asthma
who had been born at 36 weeks gestation via an unremark-
able induced vaginal delivery secondary to oligohydramnios,
with a birth weight of 5 pounds 12 ounces. The patient’s
asthma history is signiﬁcant for multiple emergency room
visits and one prior non-PICU admission for an asthma
exacerbation. His maintenance medical regimen includes
daily inhaled corticosteroids and albuterol as needed. The
patient lives with his mother, father, an older sister who is
healthy, a maternal grandmother who smokes in the house,
and a cat.2 Case Reports in Pediatrics
Figure 1: Initial chest radiograph prior to ECMO initiation.
The patient presented to a nearby emergency room seven
dayspriortopresentationwithworseningrespiratorydistress
in the context of two weeks of upper respiratory symptoms
and diarrhea. On initial presentation at the nearby emer-
gency room, he was diagnosed with bilateral pneumonia and
treated as an outpatient with amoxicillin, azithromycin, oral
steroids, and nebulized albuterol treatments. Four days after
the initial emergency room visit, his respiratory symptoms
progressed, necessitating emergency intubation and high
frequency oscillatory ventilation at the outside hospital. The
patient was positive for human metapneumovirus and had
healthy appearing airways on bronchoscopy. After three
days of progressive worsening on increased respiratory
support, the patient was transferred to the JHH Pediatric
IntensiveCareUnitfromanoutsidehospitalandvenovenous
extracorporeal membrane oxygenation was initiated. Please
refer to Figure 1 for the chest radiograph prior to ECMO
initiation.
The patient was initially treated with vancomycin, pip-
eracillin/tazobactam, and ﬂuconazole for presumed superin-
fectioninadditiontotheHMPVpneumonia.Aftertheblood
cultures were negative for bacteria, fungi, and viruses for
48 hours, vancomycin and ﬂuconazole were discontinued.
However, due to the severity of his illness and concern for
bacterial suprainfection, he completed an 11-day course of
piperacillin/tazobactam for presumptive pneumonia. Due
to decreasing urine output and concern for ﬂuid over-
load compromising his respiratory status, the patient was
started on continuous venovenous hemoﬁltration with a
positive response, and he was subsequently transitioned to a
furosemide infusion. He also required a nicardipine infusion
for elevated blood pressures. Heparin anticoagulation and
routine blood product transfusions were used during the
ECMO run as per protocol.
The patient progressed favorably from a respiratory per-
spective and was successfully decannulated on day 9 of
ECMO, extubated 4 days following ECMO, and transitioned
to room air 9 days following extubation.
Given the unusual clinical course, an immunodeﬁciency
workup to further investigate possible reasons for the de-
velopment of respiratory failure in an otherwise healthy host
was performed. T cell subsets were within normal limits. The
remainder of his hospital course on the ﬂoor was notable
for a successful diuretic wean, normalization of his work of
breathing, cleared lung exam without coarseness, subglottic
edema with intact vocal cords noted on bedside ﬂexible
laryngoscopy, and signiﬁcant strides in physical and speech
therapy.
3. Conclusion
Since its isolation in 2001 [1], HMPV has been implicated
as a signiﬁcant cause of hospitalization in infants and young
children. The literature documents detection of HMPV
in 1.5–43.0% of children with acute respiratory infections
[6]. The most commonly noted clinical manifestations
include cough, coryza, fever, irritability, anorexia, wheezing,
diarrhea, and vomiting, [7] with a wide spectrum of disease
ranging from mild upper respiratory tract disease to severe
respiratory distress requiring mechanical ventilation [1].
Because young children have smaller airways, decreased
respiratory reserve, increased oxygen consumption and
metabolic demands, and less robust compensatory mecha-
nisms, it is important to be cognizant that this population
can progress to severe respiratory failure more quickly than
their older counterparts. In the case of our patient, he
required emergency intubation after failing four days of
outpatient therapy for bilateral pneumonia. It is possible
that if he had been brought to medical attention during
the four days after being seen in the emergency department
those signs of early respiratory distress secondary to HMPV,
such as increasing tachypnea, retractions, nasal ﬂaring, and
tachycardia, would have been recognized. Earlier diagnosis
may have enabled a favorable response to less invasive
therapies and in turn prevented the need for the escalation
of respiratory support with ECMO.
Given the severity of his respiratory failure at presen-
tation, the patient was promptly placed on mechanical
ventilation and soon thereafter escalated to ECMO. Evi-
dence suggests that early ECMO intervention in children
with reversible respiratory failure may prevent ventilator-
associated lung injury and may improve survival [8, 9].
Although further research is needed to identify which
patients are most likely to beneﬁt and determine the optimal
timing for initiating ECMO, our case indicates that ECMO
was a successful rescue strategy in this case.
In summary, the goals of this case report are as follows:
(1) alert clinicians to the possibility of HMPV as a cause of
respiratory failure in an older age group of immunocompe-
tent pediatric hosts than previously considered, particularly
those with underlying airway disease such as asthma, (2)
highlight the importance of early recognition of respiratory
failure and the role that timely appreciation of this problem
mayplayinmodulatingtheneedforescalationinrespiratory
support, (3) suggest that timely utilization of ECMO was a
key player in the survival of our patient and that it shouldCase Reports in Pediatrics 3
be considered in similar patients with reversible respiratory
failure.
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